Dr. Hal Mitnick, MD

Dr. Mitnick practices at NYU Langone Perlmutter Cancer Center - 34th St in New York, New York.

Dr. Mitnick's NPI, 1306819784, was assigned on February 8, 2006. Dr. Mitnick graduated from New York University School of Medicine in 1972. Dr. Mitnick holds New York license 118418.

Dr. Mitnick's primary practice is NYU Langone Perlmutter Cancer Center - 34th St, at 14 Wall St, New York, NY 10005 in New York County. The practice phone is (212) 263-1481.

Dr. Mitnick's primary practice is NYU Langone Perlmutter Cancer Center - 34th St in New York, New York. Dr. Mitnick is also affiliated with Tisch Hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mitnick practices. Vendor and product names are available with a free account.

Rheumatology is Dr. Mitnick's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Mitnick is board certified in internal medicine by the American Board of Internal Medicine. Dr. Mitnick is licensed in New York.

Dmand AI lists acute gastroduodenitis, acute kidney failure, acute mini-stroke (TIA), acute skin infection, arteritis, arthritis, atrial fibrillation and flutter and bursitis among the conditions Dr. Mitnick treats.

CMS data shows 1,215 Medicare services from Dr. Mitnick across 8 procedure codes in 2024, for 309 Medicare patients. Medicare paid $62,526 for them. Every service was in an office.

CMS counts 309 Medicare patients who saw Dr. Mitnick in 2024. The largest group is 75 to 84, with 146 patients. 75% of them have arthritis, and 75% have high cholesterol. Their average risk score is 1.17, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Mitnick's median patient age at 74, with 72% women.

In 2024, Dr. Mitnick wrote 2,131 Medicare Part D claims for 228 patients. 79% of them were for generic drugs. CMS names the drug for 1,826 of them, across 58 drugs with 11 or more claims each, at $1,811,952 in total drug cost. In 2023, CMS named 1,649 claims across 52 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 24 out of 100 for Dr. Mitnick for performance year 2024, reported individually. Dr. Mitnick accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mitnick as offering telehealth.

Dmand AI links 19 papers to Dr. Mitnick, published from 2004 to 2013. The most frequent topics are Drug-Related Side Effects and Adverse Reactions, Giant Cell Arteritis and Immunosuppressive Agents. Dr. Mitnick has published most often in JAMA. Dr. Mitnick's most frequent co-authors are Adam Mor, MD, Stephen Alan Paget, MD and Mark A. Eberle, MD.

CMS Open Payments shows 16 general payments to Dr. Mitnick from 6 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 73% of the total. Novartis Pharmaceuticals Corporation paid the most, $185.

Dmand AI lists 7 awards for Dr. Mitnick, most recently America's Top Doctors in 2014.

Dr. Mitnick graduated from New York University School of Medicine in 1972. Dr. Mitnick is a member of ACR.

Dr. Mitnick is in network with 1 carrier, including CMS Medicare. Medicare plans come from the most carriers, 1. Check the plan with the practice before a visit.